tbuckley/cabot-search huggingface dataset:
SAT0015 Ultrasonographic Evaluation of Renal Arteries in Patients with Antiphospholipid Syndrome: Focus on Resistive Index and Stenosis: Table 1
Authors: C. Perricone, F. Ceccarelli, A. Gigante, L. Massaro, B. Barbano, F.R. Spinelli, C. Alessandri, R. Cianci, G. Valesini, F. Conti
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Renal involvement in antiphospholipid syndrome (APS) is still relatively unknown and probably underestimated. The main lesions consist of renal artery stenosis (RAS), venous renal thrombosis, and glomerular lesions. The resistive index (RI) of intra-renal arteries, indicating vascular resistance, has been evaluated in different nephropathies showing an association with functional parameters and histological features. Nonetheless, there are no studies in patients with APS. <h3>Objectives</h3> We aimed to evaluate the renal arteries RI, by color-Doppler ultrasonography (US), in a group of patients affected by APS. <h3>Methods</h3> We enrolled patients with primary APS (PAPS-Sapporo revised criteria), patients with APS secondary to Systemic Lupus Erythematosus (SAPS-1997 ACR criteria) and subjects positive for antiphospholipid antibodies without clinical manifestations (aPL-carriers). All patients underwent clinical assessment (anamnestic data and traditional risk factors for cardiovascular disease), and laboratory evaluation (anti-cardiolipin, anti-β<sub>2</sub> glycoprotein I, lupus anticoagulant, C3 and C4 serum levels). US Doppler assessment was performed, RI&gt;0.7 was considered pathologic. <h3>Results</h3> We enrolled 11 patients with PAPS, 22 patients with SAPS and 11 aPL-carriers. The clinical and laboratory features are described in Table. Pathologic RI was detected in 27.3% of SAPS patients compared to 9.1% of PAPS and aPL-carriers (P=NS). A significant correlation between the mean RI and the presence of hypertension (Spearman9s test P&lt;0.001, r=0.838) and diabetes (P&lt;0.001, r=0.861) was observed in PAPS patients. Interestingly, RAS was observed only in patients with PAPS (3/11, 27.3%) and in none of SAPS and aPL-carriers. Finally, the presence of stenosis was not associated with a pathologic RI. <h3>Conclusions</h3> We evaluated for the first time the intra-renal artery RI in APS patients: a pathological RI was detected mostly in SAPS patients. Conversely, RAS was detected only in PAPS patients. These results could suggest a different diathesis in the pathogenesis of the renal vascular manifestations in patients with APS. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5631
Abstract 5231: Tilmaocept: A novel biotargeted agent for enhanced intraoperative discrimination of sentinel lymph nodes in breast cancer, melanoma, and head &amp; neck SCC
Authors: Frederick O. Cope, Wendy Rich Metz, Simon Blackburn, Bonnie Abbruzzese, Richard Orahood
Journal: Cancer Research (2011)

Abstract Sentinel lymph node (SLN) mapping and identification is a primary component of surgical therapies for breast cancers, melanomas, pediatric soft tissue sarcomas, and certain other cancers. The current standard of care for identifying SLNs to inject into a tumor (or near a tumor) a blue dye (often called “vital blue dye”), of which several are available, in conjunction with a radiolabeled (99mTc) tracer, available as either a technetium sulfur colloid or as a technetium labeled albumin formulation. The exact formulations used vary, especially between those used in the United States and Europe. All such compounds are effectively agents of passive transport in the lymphatic ducts and are “inert” with regard to any biomarker recognition specificity. Allegedly, such agents move passively from the tumor/tumor basin into lymph nodes with a presumptive tumor-node anatomic nexus and the nodes are elucidated as blue and/or radioactive, the former based on excision line-of-sight, the latter based on intraoperative evaluation with a gamma-detecting probe. But because such components do not bear any specificity, that is, bind or accumulate lymph nodes bearing targets, they either remain static at the injection site and/or quickly drain away, reducing their real-time clinical effectiveness. A novel 99mTc-labeled, prospectively designed, low Mr molecule (99mTc DTPA Mannosyl Dextran; Tilmanocept) targeted as a ligand for the mannose binding receptor (MBR) of lymphatic reticuloendothelial cells and intended for real-time intraoperative gamma mapping of tumor-lymphatic nexuses has been synthesized and clinically tested in Phase 3 clinical studies in breast cancer and melanoma. The results of the development process and clinical testing indicate: 1) The prospective molecular designs resulted in safety and clinical performance characteristics that provided times from agent injection to patient evaluation that were significantly reduced compared to currently applied 99mTc-labeled agents; and 2) The specificity, sensitivity, and performance with regard to anatomic localization, false negative rates, and receptor retention exceed those of other colorimetric and 99mTc-labeled agents. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5231. doi:10.1158/1538-7445.AM2011-5231
Abstract 5344: IGF1-receptor expression is regulated by miR-100 in metastatic pancreatic cancer cells.
Authors: Justin S. Huang, Michael Egger, William E. Grizzle, Lacey R. McNally
Journal: Cancer Research (2013)

Abstract Patients with pancreatic adenocarcinoma have the lowest 5-year survival and yearly rates of incidence are almost equivalent to the mortality rates. Long-term cure rates by standard therapies are disappointing due to disseminated disease at diagnosis and chemotherapeutic resistance. New therapeutic targets are necessary for decreasing the progression of pancreatic cancer and identifying targets specific to metastasis would improve patient care. In this study, we evaluated the levels of microRNA of metastatic and non-metastatic cell lines. The expression level of microRNAs and mRNAs were identified through microarray analysis by examining and comparing 5 pancreatic cancer cell lines, two that can metastasize in vivo (S2VP10, S2CP9) versus three that do not metastasize (MiaPaCa2, Panc-1, and ASPC-1). MicroRNA analysis indicated an increase in miR-100 and a decrease in miR-138 expression in metastatic cancer cells. Microarray analysis of differentially expressed mRNAs between metastatic and non-metastatic pancreatic cell lines also indicated increased insulin growth factor-1 receptor (IGF1-R) expression (p&amp;lt;0.0001) in metastatic pancreatic cancer cell lines compared to non-metastatic pancreatic cancer cell lines. To confirm these results from microarray analysis, western blot and immunocytochemistry was performed. Western blot revealed IGF1-R expression was 7 fold increased in metastatic cancer cell lines compared to non-metastastatic cell lines. In addition, downstream expressions of proteins GRB2 and phosphorylated PI3K also were increased in aggressive cancer cell lines. Immunocytochemistry confirmed the linkage of IGF1-R to miR-100 as cells transfected with miR-100 inhibitor showed a decrease in IGF1-R. However, cells transfected with a miR-138 mimic did not affect IGF1-R expression. IGF1-R may be an important molecular feature and a useful biomarker for diagnosis and treatment of metastatic pancreatic cancer. Citation Format: Justin S. Huang, Michael Egger, William E. Grizzle, Lacey R. McNally. IGF1-receptor expression is regulated by miR-100 in metastatic pancreatic cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5344. doi:10.1158/1538-7445.AM2013-5344
Scintigraphy of a Double Renal Transplant From an Infant Donor
Authors: CARLOS E. JIMÉNEZ
Journal: Clinical Nuclear Medicine (1999)

Renal scintigraphy was performed to rule out a urinary leak on a 47-year-old woman a few days after she underwent pediatric cadaver kidney transplantation. Because of the chronic shortage of donor organs, paired pediatric kidneys (from donors younger than 5 years old) are increasingly transplanted using en bloc extraperitoneal anastomosis of the donor aorta and vena cava into the recipient's external iliac artery and vein. The transplantation of two infant kidneys into one recipient doubles the amount of functional renal mass and increases the chance of good long-term renal function. The postoperative scintigraphic evaluation did not show any abnormality.
Place de l'endoscopie en urgence dans la prise en charge des corps étrangers ingérés. A propos de 82 cas
Authors: I Mellouki, N Khalil, N Lazaar, M El Yousfi, N Aqodad, DA Benajah, M El Abkari, A Ibrahimi
Journal: Endoscopy (2011)

Les corps étrangers ingérés sont fréquents, nombreux mais mal répertoriés, leur ingestion peut être accidentelle ou volontaire selon les conditions de survenue. Ils peuvent être dangereux par leur localisation ou leur nature, ce qui rend leur extraction endoscopique urgente.
605 PLASMA COPEPTIN LEVELS ARE INCREASED IN CIRRHOSIS AND CORRELATE WITH HYPONATREMIA AND CIRCULATORY DYSFUNCTION
Authors: E. Solà, R. Moreira, E. Rodriguez, R. Barreto, R. Cela, M. Morales, P. Ruiz, I. Graupera, M. Guevara, W. Jimenez, V. Arroyo, P. Ginès
Journal: Journal of Hepatology (2013)
Immunoglobulin on Tumor Cells and Tumor-Induced Lymphocyte Blastogenesis in Human Acute Leukemia
Authors: Jordan U. Gutterman, Roger D. Rossen, William T. Butler, Kenneth B. McCredie, Gerald P. Bodey, Emil J. Freireich, Evan M. Hersh
Journal: New England Journal of Medicine (1973)

Combined studies of direct membrane immunofluorescence with anti-immunoglobulin serum and of lymphocyte blastogenic responses to autologous leukemia cells were carried out in 34 adult patients with acute leukemia. Twenty-four of 34 (71 per cent) has positive blastogenic responses to their own leukemia cells. Eight of 19 patients with acute myelogenous leukemia and one of five with acute lymphoblastic leukemia had complete or partial abrogation of this positive blastogenesis when the lymphocytes were cultured in autologous rather than allogeneic serum. Direct membrane immunofluorescence with anti-immunoglobulin serum showed bound IgG on the cells of seven of eight patients with acute myelogenous leukemia and serum inhibition, and one without the serum inhibitory effect. Membrane immunofluorescence was negative in two patients with positive blastogenesis and serum inhibition, 14 of 15 with positive blastogenesis and no serum inhibition and, finally, all 10 patients with negative blastogenic responses to leukemia cells. A good prognosis was correlated with a positive blastogenic response, its inhibition by autologous serum, and IgG bound to the cell surface.
Confocal laser endomicroscopy for the diagnosis of diversion colitis
Authors: G. Hundorfean, M. Chiriac, J. Siebler, M. Neurath, J. Mudter
Journal: Endoscopy (2012)

Confocal laser endomicroscopy (CLE) and virtual chromoendoscopy (VCE) are advanced endoscopic imaging techniques. i-Scan (Pentax, Japan) is a contrast-enhancing computed program [1], while CLE enables in vivo histological examination [2] [3].
Abstract 1917: Loss of steroid sulfotransferase (SULT) in human prostate cancer: Potential implications for SULT as a biomarker and therapeutic target.
Authors: Nooshin Mirkheshti, Chung S. Song, Bandana Chatterjee
Journal: Cancer Research (2013)

Abstract Purpose: Reactivated androgen receptor, fueled by elevated tumor tissue 5α-dihydrotestosterone (DHT), plays a key role in the reemergence of prostate cancer. Primary prostate cancer almost always regresses in response to androgen deprivation therapy. The disease, however, recurs and progresses to therapy resistance and death in ∼30% patients. New-generation drugs that inhibit androgen receptor (MDV3100™) or enzymes involved in androgen biosynthesis (Zytiga™, TAK-700™, Dutasteride™) extend survival of post-chemotherapy patients for a limited period following which therapy resistance emerges– hence the challenge to develop alternate means for reducing intra-tumor androgen signaling. Design and Results: 3β-sulfation of dehydroepiandrosterone (DHEA), mediated by the prostate-expressed sulfotransferase SULT2B1b (hereon SULT), is likely to reduce intra-prostate androgen levels since sulfated DHEA cannot be converted to androstenedione and thus to testosterone and DHT. We tested whether enzyme-catalyzed sulfation of DHEA, the obligate precursor steroid for androgen synthesis, is targetable to inhibit prostate cancer. Results show that SULT silencing increased prostate cancer cell proliferation. Clinical prostate cancer specimens showed markedly reduced SULT expression, revealed by immunohistochemistry, western blotting and mRNA quantification. 1,25-dihydroxy vitamin D3 (D3) and sterols enhanced SULT expression due to induction of the SULT2B-encoding gene by D3-activated vitamin D receptor (VDR) and sterol-activated liver X receptor (LXRα). Conclusion: Tumor SULT levels may be a marker for predicting prostate cancer recurrence and progression. We also anticipate that enhancement of SULT activity in tumors by activating VDR and LXRα through combined therapeutic intervention with D3 and sterols would limit the tumor androgen pool and inhibit recurrent, therapy-resistant prostate cancer. Citation Format: Nooshin Mirkheshti, Chung S. Song, Bandana Chatterjee. Loss of steroid sulfotransferase (SULT) in human prostate cancer: Potential implications for SULT as a biomarker and therapeutic target. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1917. doi:10.1158/1538-7445.AM2013-1917
P2-18-05: Cardiotoxicity Risks of Adjuvant Trastuzumab in Asian Breast Cancer Patients.
Authors: V Shih, A Chan, MH Sim, C Teo, W Chen, ZW Wong
Journal: Cancer Research (2011)

Abstract Background: Adjuvant trastuzumab (T)-based chemotherapy reduces relapse and improves overall survival in early breast cancer. However, T-associated cardiotoxicity potentially limits its use. Our study aims to report the incidence, severity and reversibility of cardiotoxicity amongst Asian breast cancer patients. Methods: This is a retrospective review of patients who have received adjuvant T from June 2005 to March 2011 at our centre. CT was defined as a drop in left ventricular ejection fraction (LVEF) to less than 50% and / or reduction of ≥ 10% of baseline. Cardiovascular (CVS) risk factors were defined as having at least one of the following factors: family or previous history of CAD, hypertension, diabetes mellitus, hyperlipidemia and smoking. One-way repeated measures ANOVA was used to evaluate the mean LVEF change and Chi-square test to evaluate the association of demographics and CT. Results: A total of 314 female patients were reviewed. CT was reported in 124 (39.5%), of whom 96 had asymptomatic decline in LVEF and 28 were symptomatic. T was withheld (n=53) due to asymptomatic decline in LVEF (n=40), symptomatic heart failure (n=3) and both (n=10). Forty-three patients with resolution of CHF (n=11) or LVEF recovery (n=32) were rechallenged. Cardiotoxicity recurred in 14 - asymptomatic decline in LVEF (n=10), recurrent CHF (n=1) and both (n=3). Overall, there were no cardiac-related deaths. Factors that predicted for CT included low normal pre-trastuzumab LVEF (&amp;lt;60%) (p=0.01), prior anthracyclines (p=0.011), decline in LVEF pre-anthracycline and before T (p=0.022) and BMI ≥ 23kg/m2 (p=0.018). Three-monthly LVEF showed statistically significant decline against baseline over the time points (p=0.005). As expected, the decline in LVEF demonstrated significant interaction with CT groups and non CT group (p&amp;lt;0.001). Conclusions: A higher incidence of CT (39.5%) was observed among Asian breast cancer patients compared to previously reported in Caucasians (24%). Although 77.4% of patients presented with asymptomatic decline in LVEF, approximately one-third of patients experienced recurrent CT upon rechallenge. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-18-05.
Abstract 2223: Screening for oncoviruses using next-generation sequencing
Authors: Mohamed El-Dinali, Johannes Braegelmann, Ravi Salgia, Tanguy Seiwert
Journal: Cancer Research (2010)

Abstract Introduction: During the last decades numerous viruses have been found to play a causative role in cancer. Besides well established connections like HPV in cancers of the uterine cervix or EBV in nasopharyngeal carcinoma recent advances in next-generation sequencing technologies have led to the discovery of new tumor viruses e.g. a previously unknown Polyoma-virus subtype linked to Merkel-cell carcinoma of the skin. Method: To gain insight into the mechanisms leading to tumor formation we sequenced the transcriptome from an HPV16 positive cell line using short-read Illumina RNA-Seq and established a computational pipeline to screen the short reads for viral sequences based on freely available alignment tools. Results: Due to the large amount of data and in order to narrow down the search space and reduce the chance for false positives the first screening step consists in a subtraction of sequences that align to the human reference genome reducing the amount of reads by ∼70%. To find both known viruses and yet unknown strains/subtypes we apply a two-fold approach: 1. A rapid search for known viruses is done using a short-read alignment tool with a set of stringent parameters to map non-human reads to an index of the viral genbank and subsequent quantification of the hits. 2. Since slight differences between read and index sequence will cause the rapid search to not call a match we implemented a more lenient approach using standalone BLAST. Applying approach 1) to the control cell line we clearly identified HPV16 as being present. To test the possibility of finding a potentially unknown virus we deleted HPV16 from both the rapid approach and the index which caused the first algorithm to no longer identify the virus. Running the BLAST basec approach 2) resulted in multiple hits the most prominent being alignments to HPV subtypes 35 and 58, thus indicating the successful identification of related strains. Conclusion: We demonstrated the feasibility of our dual viral screening approach in an in-silico experiment using an HPV16 positive control. Our approach appears to be able to identify novel related viruses. In the future this will allow screening of patient samples and viral screening was added to our data pipeline. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2223.
Porphyria Cutanea Tarda
Authors: Chih-Chieh Chan, Sung-Jan Lin
Journal: New England Journal of Medicine (2011)

A 51-year-old man with a history of heavy alcohol use, chronic HCV infection, and hepatic cirrhosis presented with an 8-month history of periorbital hair growth. Healing crusts and scars were evident in sun-exposed areas, and his urine had pink fluorescence under a Wood's lamp.
Endoscopic Ultrasonography for Gastrointestinal Submucosal Tumors: Long Dozen of Clinical Experience
Authors: SG Shapovalyantz, SY Orlov, ZV Galkova, RV Plakhov, LM Michaleva, ED Fedorov
Journal: Endoscopy (2011)

Aim: During the last years diagnostics and treatment of gastrointestinal submucosal tumors (SMT) have been significantly changed due to the introduction of immunohistochemistry, advanced imaging and operative techniques. To determine the practical importance of endoscopic ultrasonography (EUS) in diagnostics of SMT of the upper gastrointestinal tract and to clarify the role of EUS in settling on surgical tactics.
Abstract 276: Targeting signaling networks via RNAi to improve therapy for ovarian cancer
Authors: Hanqing Liu, Ilya Serebriiskii, Margret B. Einarson, Anna Pecherskaya, Yan Zhou, Harsh Pathak, Andrew K. Godwin, Erica A. Golemis
Journal: Cancer Research (2012)

Abstract Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy, and the leading cause of death from gynecological cancers. At the time of presentation, most ovarian cancers are no longer dependent on single genetic determinants for growth and/or survival, and targeted therapies used as single agents typically do not work in this disease. We hypothesized that network-based synthetic lethality screens would help identify critical pathways to target in combination therapy. We have used RNAi screening with a targeted library to identify a set of gene candidates that influence the response of EOC cells to the Src-targeting agent dasatinib, a promising agent for treatment of EOC. We identified sets of siRNAs that specifically modulated cell resistance to dasatinib, or directly affected EOC cell survival. We then compared this set of siRNAs with previously identified modulators of response to EGFR-targeting agents and cytotoxic drugs, contrasting action in EOC cell lines versus other types of cancer cell lines. From a set of 60 siRNAs intrinsically reducing cell growth and survival, some (16 siRNAs) were specific for EOC cells. In contrast, 38 siRNAs antagonized the response of EOC cells to dasatinib, and are promising drug treatment-resistance biomarkers. We concluded validation of EOC-specific hits. Mapping the pattern of drug treatment-resistance hits together with drug treatment-sensitive hits revealed suggestive clusters of very closely interacting proteins clustering with well validated modulators of cancer cell survival, implying we have identified key cancer signaling nodes. Screening candidates, e.g., PTPN12, Spry4, and HSPA8, which cluster with well-validated cancer-related signaling hubs, are being examined. These studies offer an opportunity to employ a functional approach to identify critical drug response-modifying genes that can be therapeutically targeted as biomarkers and drug targets to improve EOC treatment outcomes with emerging targeted agents. (This work was supported by the fellowship grant from Sass Foundation for Medical Research, Inc, Roslyn, New York to H. Liu, NIH FCCC-UPenn ovarian cancer SPORE (P50 CA083638), and NIH (R01 CA140323).) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 276. doi:1538-7445.AM2012-276